Back
Blueprint Medicines Quote, Financials, Valuation and Earnings
"This Changes Everything" - Trump Hands Millions Massive IRS Gift
Learn More Here
Sell
37
BPMC
Blueprint Medicines
Last Price:
94.81
Seasonality Move:
-0.18%
7 Day Trial
ALL ACCESS PASS
$
7
Trump's IRS Hands Massive 'Victory Gift' To 401K Owners
Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.Blueprint Medicines Price Quote
$94.81
Blueprint Medicines Key Stats
Sell
37
Blueprint Medicines (BPMC)
is a Sell
Day range:
$92.66 - $95.02
52-week range:
$63.50 - $121.90
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.02
P/B ratio:
18.29%
Volume:
555.4K
Avg. volume:
673.7K
1-year change:
43.91%
Market cap:
$5.7B
Revenue:
$249.4M
EPS:
$-2.11
How Much Does Blueprint Medicines Make?
-
How Much Are Blueprint Medicines's Sales Annually?
BPMC Revenues are $249.4M -
How Much Profit Does Blueprint Medicines's Make A Year?
BPMC net income is -$507M
Is Blueprint Medicines Growing As A Company?
-
What Is Blueprint Medicines's Growth Rate Quarterly?
Quarterly YoY revenue growth is 1.27% -
What Is Blueprint Medicines's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Blueprint Medicines Stock Price Performance
-
Did Blueprint Medicines Stock Go Up Last Month?
Blueprint Medicines share price went up by 10.24% last month -
Did BPMC's Share Price Rise Over The Last Year?
BPMC share price rose by 43.91% over the past 1 year
What Is Blueprint Medicines 52-Week High & Low?
-
What Is Blueprint Medicines’s 52-Week High Share Price?
Blueprint Medicines has traded as high as $121.90 over the past 52 weeks -
What Is Blueprint Medicines’s 52-Week Low Share Price?
Blueprint Medicines has traded as low as $63.50 over the past 52 weeks
Blueprint Medicines Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Blueprint Medicines?
-
How Much Debt Does Blueprint Medicines Have?
Total long term debt quarterly is $386.6M -
How Much Cash Does Blueprint Medicines Have?
Cash and short term investments quarterly total is $734.2M -
What Is Blueprint Medicines’s Book Value Per Share?
Book value per share is 4.94
Is Blueprint Medicines Cash Flow Positive?
-
What Is BPMC Cash Flow From Operations?
Cash flow from operations (TTM) is -$242.2M -
What Is Blueprint Medicines’s Cash Flow From Financing?
Cash flow from financing (TTM) is $278.9M -
What Is Blueprint Medicines’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$2.4M
Blueprint Medicines Return On Invested Capital
-
Is Management Doing A Good Job?
BPMC return on invested capital is -23.14% -
What Is Blueprint Medicines Return On Assets?
ROA measures how assets are converting to revenues and is -11.44% -
What Is BPMC Return On Equity?
ROE is a measure of profitability and is -50.13%
Blueprint Medicines Earnings Date & Stock Price
-
What Is Blueprint Medicines's Stock Price Today?
A single share of BPMC can be purchased today for 94.81 -
What Is Blueprint Medicines’s Stock Symbol?
Blueprint Medicines trades on the nasdaq under the ticker symbol: BPMC -
When Is Blueprint Medicines’s Next Earnings Date?
The next quarterly earnings date for Blueprint Medicines is scheduled on February 14, 2025 -
When Is BPMC's next ex-dividend date?
Blueprint Medicines's next ex-dividend date is November 21, 2024 -
How To Buy Blueprint Medicines Stock?
You can buy Blueprint Medicines shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Blueprint Medicines Competitors
-
Who Are Blueprint Medicines's Competitors?
Below is a list of companies who compete with Blueprint Medicines or are related in some way:
Blueprint Medicines Dividend Yield
-
What Is BPMC Dividend Yield?
Blueprint Medicines’s dividend yield currently is 0% -
What Is Blueprint Medicines’s Payout Ratio?
Blueprint Medicines’s payout ratio is 0% -
When Did Blueprint Medicines Last Pay A Dividend?
The latest dividend pay date is November 21, 2024 -
What Is Blueprint Medicines’s Dividend Per Share?
Blueprint Medicines pays a dividend of $0.00 per share
Blueprint Medicines Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 7.41% |
| Revenue: | 126.61% | 0.56% |
Analyst Recommendations
| Buy Recommendations: | 9 |
|---|---|
| Hold Recommendations: | 5 |
| Sell Recommendations: | 1 |
| Price Target: | 125.58 |
| Upside from Last Price: | 32.45% |